单硝酸异山梨酯缓释片联合美托洛尔对冠心病心力衰竭患者血浆BNP的影响

Effect of isosorbide mononitrate sustained-release tablets combined with metoprolol on plasma BNP in patients with coronary disease complicated with heart failure

目的探讨单硝酸异山梨酯缓释片联合美托洛尔治疗冠心病心力衰竭患者的临床疗效及对血浆BNP的影响。方法选择我科室收治的200例冠心病心力衰竭患者,随机分为对照组(100例)和观察组(100例)。对照组患者采取常规抗心衰治疗,观察组患者在对照组治疗基础上采用单硝酸异山梨酯缓释片联合美托洛尔治疗。观察对比两组的治疗总有效率以及治疗前、后的收缩压(SBP)、左室射血分数(LVEF)及血浆脑钠肽(BNP)水平。结果观察组患者的治疗总有效率为94.00%,明显高于对照组的85.00%(P<0.05)。治疗后,两组患者的SBP、血浆BNP水平明显下降,LVEF水平明显升高,且观察组患者的SBP、LVEF及BNP水平明显优于对照组(P<0.05)。结论单硝酸异山梨酯缓释片联合美托洛尔治疗冠心病心力衰竭患者的临床效果显著,能显著降低血浆BNP水平,并对心功能有明显的改善效果。

Objective To explore the clinical effect of isosorbide mononitrate sustained-release tablets combined with metoprolol in the treatment of coronary disease complicated with heart failure and its effect on plasma BNP. Methods Two hundred cases of patients with coronary disease complicated with heart failure were selected and randomly divided into control group（n=100） and observation group（n=100）. The control group was treated with routine CHF treatment, and the observation group was given isosorbide mononitrate sustained-release tablets combined with metoprolol on the basis of the control group. The clinical effects, the levels of SBP, LVEF and plasma BNP before and after treatment of the two groups were compared. Results The total effective rate of the observation group was 94.00%, which was higher than 85.00% of the control group（P〈0.05）. After treatment, the SBP and plasma BNP levels of the two groups decreased, the LVEF levels of two groups increased, and levels of SBP, LVEF and plasma BNP of the observation group were better than those of the control group（P〈0.05）. Conclusion Isosorbide mononitrate sustained-release tablets combined with metoprolol in patients with coronary disease complicated with heart failure has significant clinical effect, which can decrease the plasma BNP level and improve the cardiac function significantly.